Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome

Endocrine Practice

Volumn 14, Issue 9, 2008, Pages 1180-1187

  Farwell, Alan P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; HYDROCORTISONE; INSULIN; LEVOTHYROXINE; LIOTHYRONINE; METHYLPREDNISOLONE; THYROTROPIN; THYROXINE; VASOPRESSIN; THYROID HORMONE;

BRAIN DEATH; CARDIOPULMONARY BYPASS; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; EUTHYROID SICK SYNDROME; GESTATIONAL AGE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART OUTPUT; HEART SURGERY; HORMONAL THERAPY; HUMAN; HYPOTHYROXINEMIA; INTELLIGENCE QUOTIENT; INTENSIVE CARE UNIT; NERVE CELL DIFFERENTIATION; NEWBORN MORTALITY; NOTE; PREMATURITY; RESPIRATORY DISTRESS; THYROID DISEASE; THYROXINE BLOOD LEVEL; BLOOD; CRITICAL ILLNESS; DRUG CONTRAINDICATION; DRUG EFFECT; EVALUATION; HEART; HORMONE SUBSTITUTION; MORTALITY; NEWBORN; PATIENT SELECTION; REVIEW; STARVATION;

CRITICAL ILLNESS; EUTHYROID SICK SYNDROMES; HEART; HORMONE REPLACEMENT THERAPY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS; PATIENT SELECTION; STARVATION; THYROID HORMONES;

EID: 64049099506     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.9.1180     Document Type: Note

References (94)

1. Farwell AP. Sick euthyroid syndrome in the intensive care unit. In: Irwin RS, Rippe JM, eds. Irwin and Rippe's Intensive Care Medicine. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003: 1205-1216.
2. DeGroot LJ. "Non-thyroidal illness syndrome" is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge. J Endocrinol Invest. 2003;26:1163-1170.
3. Adler SM, Wartofsky L. The nonthyroidal illness syndrome. Endocrinol Metab Clin North Am. 2007;36:657-672, vi.
4. Brierre S, Kumari R, Deboisblanc BP. The endocrine system during sepsis. Am J Med Sci. 2004;328:238-247.
5. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350:1629-1638.
6. Chopra IJ. Euthyroid sick syndrome: abnormalities in circulating thyroid hormones and thyroid hormone physiology in nonthyroid illnesses. Medical Grand Rounds. 1982; 1:201-212.
7. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." Endocr Rev. 1982;3:164-217.
8. Mebis L, Langouche L, Visser TJ, Van den Berghe G. The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab. 2007;92:3330-3333.
9. Peeters RP,Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003;88:3202-3211.
10. Peeters RP, van der Geyten S, Wouters PJ, et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab. 2005;90:6498-6507.
11. Kaptein EM, Weiner JM, Robinson WJ, Wheeler WS, Nicoloff JT. Relationship of altered thyroid hormone indices to survival in nonthyroidal illnesses. Clin Endocrinol (Oxf). 1982;16:565-574.
12. Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism. 2007; 56:239-244.
13. Slag MF, Morley JE, Elson MK, Crowson TW, Nuttall FQ, Shafer RB. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA. 1981;245:43-45.
14. Iervasi G, Pingitore A, Landi P, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107:708-713.
15. Pingitore A, Landi P, Taddei MC, Ripoli A, L'Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118: 132-136.
16. Vexiau P, Perez-Castiglioni P, Socié G, et al. The "euthyroid sick syndrome": incidence, risk factors and prognostic value soon after allogeneic bone marrow transplantation. Br J Haematol. 1993;85:778-782.
17. DeGroot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999; 84:151-164.
18. Stathatos N, Levetan C, Burman KD,Wartofsky L. The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab. 2001;15:465-478.
19. Stathatos N, Wartofsky L. The euthyroid sick syndrome: is there a physiologic rationale for thyroid hormone treatment? J Endocrinol Invest. 2003;26:1174-1179.
20. Peeters RP,Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab. 2005;90:4559-4565.
21. Bianco AC, Larsen PR. Intracellular pathways of iodothyronine metabolism. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005: 109-134.
22. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173-189.
23. Visser TJ, Lamberts SW, Wilson JH, Docter R, Hennemann G. Serum thyroid hormone concentrations during prolonged reduction of dietary intake. Metabolism. 1978;27:405-409.
24. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med. 1979; 300:579-584.
25. Koppeschaar HP, Meinders AE, Schwarz F. Metabolic responses in grossly obese subjects treated with a verylow-calorie diet with and without triiodothyronine treatment. Int J Obes. 1983;7:133-141.
26. Byerley LO, Heber D. Metabolic effects of triiodothyronine replacement during fasting in obese subjects. J Clin Endocrinol Metab. 1996;81:968-976.
27. Richmand DA, MolitchME, O'Donnell TF. Altered thyroid hormone levels in bacterial sepsis: the role of nutritional adequacy. Metabolism. 1980;29:936-942.
28. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low thyroxine concentration. J Clin Endocrinol Metab. 1986;63:1-8.
29. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000;57:293-298.
30. Acker CG, Flick R, Shapiro R, et al. Thyroid hormone in the treatment of post-transplant acute tubular necrosis (ATN). Am J Transplant. 2002;2:57-61.
31. Becker RA, Vaughan GM, Zeigler MG, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med. 1982;10:870-875.
32. Obregon MJ, Calvo RM, Del Rey FE, de Escobar GM. Ontogenesis of thyroid function and interactions with maternal function. Endocr Dev. 2007;10:86-98.
33. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med. 1994;331:1072-1078.
34. Fisher DA. Euthyroid low thyroxine (T4) and triiodothyronine (T3) states in premature and sick neonates. Pediatr Clin North Am. 1990;37:1297-1312.
35. Reuss ML, Leviton A, Paneth N, Susser M. Thyroxine values from newborn screening of 919 infants born before 29 weeks' gestation. Am J Public Health. 1997;87:1693-1697.
36. Uhrmann S, Marks KH, Maisels MJ, Kulin HE, Kaplan M, Utiger R. Frequency of transient hypothyroxinaemia in low birthweight infants: potential pitfall for neonatal screening programmes. Arch Dis Child. 1981;56:214-217.
37. Frank JE, Faix JE, Hermos RJ, et al. Thyroid function in very low birth weight infants: effects on neonatal hypothyroidism screening. J Pediatr. 1996;128:548-554.
38. Bernal J. Thyroid hormones and brain development. Vitam Horm. 2005;71:95-122.
39. Rovet J, Daneman D. Congenital hypothyroidism: a review of current diagnostic and treatment practices in relation to neuropsychologic outcome. Paediatr Drugs. 2003;5:141-149.
40. Anderson GW. Thyroid hormones and the brain. Front Neuroendocrinol. 2001;22:1-17.
41. Hadeed AJ, Asay LD, Klein AH, Fisher DA. Significance of transient postnatal hypothyroxinemia in premature infants with and without respiratory distress syndrome. Pediatrics. 1981;68:494-498.
42. Reuss ML, Paneth N, Pinto-Martin JA, Lorenz JM, Susser M. The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age. N Engl J Med. 1996;334:821-827.
43. Den Ouden AL, Kok JH, Verkerk PH, Brand R, Verloove-Vanhorick SP. The relation between neonatal thyroxine levels and neurodevelopmental outcome at age 5 and 9 years in a national cohort of very preterm and/or very low birth weight infants. Pediatr Res. 1996;39:142-145.
44. Chowdhry P, Scanlon JW, Auerbach R, Abbassi V. Results of controlled double-blind study of thyroid replacement in very low-birth-weight premature infants with hypothyroxinemia. Pediatrics. 1984;73:301-305
45. vanWassenaer AG, Kok JH, de Vijlder JJ, et al. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. N Engl J Med. 1997;336:21-26.
46. Briët JM, van Wassenaer AG, Dekker FW, de Vijlder JJ, van Baar A, Kok JH. Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age. Pediatrics. 2001;107:712-718.
47. Smith LM, Leake RD, Berman N, Villanueva S, Brasel JA. Postnatal thyroxine supplementation in infants less than 32 weeks' gestation: effects on pulmonary morbidity. J Perinatol. 2000;20:427-431.
48. Vanhole C, Aerssens P, Naulaers G, et al. L-thyroxine treatment of preterm newborns: clinical and endocrine effects. Pediatr Res. 1997;42:87-92.
49. Amato M, Guggisberg C, Schneider H. Postnatal triiodothyronine replacement and respiratory distress syndrome of the preterm infant. Horm Res. 1989;32:213-217.
50. Osborn DA. Thyroid hormones for preventing neuro-developmental impairment in preterm infants. Cochrane Database Syst Rev. 2001;(4):CD001070.
51. Klein I, Danzi S. Thyroid disease and the heart [published correction appears in Circulation. 2008;117:e18]. Circulation. 2007;116:1725-1735.
52. Danzi S, Klein I. Thyroid hormone-regulated cardiac gene expression and cardiovascular disease. Thyroid. 2002;12: 467-472.
53. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
54. Wiersinga WM, Lie KI, Touber JL. Thyroid hormones in acute myocardial infarction. Clin Endocrinol (Oxf). 1984;14:367-374.
55. Worstman J, Premachandra BN, Chopra IJ, Murphy JE. Hypothyroxinemia in cardiac arrest. Arch Intern Med. 1987;147:245-248.
56. Longstreth WT Jr, Manowitz NR, DeGroot LJ, et al. Plasma thyroid hormone profiles immediately following out-of-hospital cardiac arrest. Thyroid. 1996;6:649-653.
57. Facktor MA, Mayor GH, Nachreiner RF, D'Alecy LG. Thyroid hormone loss and replacement during resuscitation from cardiac arrest in dogs. Resuscitation. 1993;26: 141-162.
58. Iltumur K, Olmez G, Ariturk Z, Taskesen T, Toprak N. Clinical investigation: thyroid function test abnormalities in cardiac arrest associated with acute coronary syndrome. Crit Care. 2005;9:R416-R424.
59. Bremner WF, Taylor KM, Baird S, et al. Hypothalamopituitary- thyroid axis function during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1978;75:392-399.
60. Chu SH, Huang TS, Hsu RB, Wang SS, Wang CJ. Thyroid hormone changes after cardiovascular surgery and clinical implications. Ann Thorac Surg. 1991;52:791-796.
61. Robuschi G, Medici D, Fesani F, et al. Cardiopulmonary bypass: "a low T4 and T3 syndrome" with blunted thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH). Horm Res. 1986;23:151-158.
62. Clark RE. Cardiopulmonary bypass and thyroid hormone metabolism [with discussion]. Ann Thorac Surg. 1993;56(1suppl):S35-S42.
63. ReinhardtW, Mocker V, Jockenhövel F, et al. Influence of coronary artery bypass surgery on thyroid hormone parameters. Horm Res. 1997;47:1-8.
64. Holland FW II, Brown PS Jr, Weintraub BD, Clark RE. Cardiopulmonary bypass and thyroid function: a "euthyroid sick syndrome." Ann Thorac Surg. 1991;52:46-50.
65. Broderick TJ, Wechsler AS. Triiodothyronine in cardiac surgery. Thyroid. 1997;7:133-137.
66. Cerillo AG, Sabatino L, Bevilacqua S, et al. Nonthyroidal illness syndrome in off-pump coronary artery bypass grafting. Ann Thorac Surg. 2003;75:82-87.
67. Cerillo AG, Storti S, Mariani M, et al. The non-thyroidal illness syndrome after coronary artery bypass grafting: a 6-month follow-up study. Clin Chem Lab Med. 2005;43:289-293.
68. Afandi B, Schussler GC, Arafeh AH, Boutros A, Yap MG, Finkelstein A. Selective consumption of thyroxine-binding globulin during cardiac bypass surgery. Metabolism. 2000;49:270-274.
69. Novitzky D, Human PA, Cooper DK. Inotropic effect of triiodothyronine following myocardial ischemia and cardiopulmonary bypass: an experimental study in pigs. Ann Thorac Surg. 1988;45:50-55.
70. Novitzky D, Human PA, Cooper DK. Effect of triiodothyronine (T3) on myocardial high energy phosphates and lactate after ischemia and cardiopulmonary bypass: an experimental study in baboons. J Thorac Cardiovasc Surg. 1988;96:600-607.
71. Novitzky D, Matthews N, Shawley D, Cooper DK, Zuhdi N. Triiodothyronine in the recovery of stunned myocardium in dogs [with discussion]. Ann Thorac Surg. 1991;51:10-17.
72. Kazmierczak P, Polak A, Mussur M. Influence of preischemic short-term triiodothyronine administration on hemodynamic function and metabolism of reperfused isolated rat heart. Med Sci Monit. 2004;10:BR381-BR387.
73. Novitzky D, Cooper DK, Swanepoel A. Inotropic effect of triiodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: an initial experience in patients undergoing open heart surgery. Eur J Cardiothorac Surg. 1989;3:140-145.
74. Novitzky D, Cooper DK, Barton CI, et al. Triiodothyronine as an inotropic agent after open heart surgery [with discussion]. J Thorac Cardiovasc Surg. 1989;98(5, pt 2):972-978.
75. Teiger E, Menasché P, Mansier P, et al. Triiodothyronine therapy in open-heart surgery: from hope to disappointment. Eur Heart J. 1993;14:629-633.
76. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333:1522-1527.
77. Klemperer JD, Klein IL, Ojamaa K, et al. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations [with discussion]. Ann Thorac Surg. 1996;61:1323-1329.
78. Bennet-Guerrero E, Jimenez JL, White WD, D'Amico EB, Bladwin BI, Schwinn DA (Duke T3 Study Group). Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled trial. JAMA. 1996;275:687-692.
79. Bettendorf M, Schmidt KG, Grulich-Henn J, Ulmer HE, Heinrich UE. Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study. Lancet. 2000;356:529-534.
80. Chowdhury D, Ojamaa K, Parnell VA, McMahon C, Sison CP, Klein I. A prospective randomized clinical study of thyroid hormone treatment after operations for complex congenital heart disease. J Thorac Cardiovasc Surg. 2001;122:1023-1025.
81. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid. 1997;7:139-145.
82. Novitzky D. Novel actions of thyroid hormone: the role of triiodothyronine in cardiac transplantation. Thyroid. 1996; 6:531-536.
83. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006;82: 1396-1401.
84. Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996;83:41-47.
85. Jeevanandam V, Todd B, Regillo T, Hellman S, Eldridge C, McClurken J. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy [with discussion]. J Heart Lung Transplant. 1994;13:681-687.
86. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, VA. Circulation. 2002;106:836-841.
87. Morkin E, Pennock GD, Raya TE, Bahl JJ, Goldman S. Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure. Ann Thorac Surg. 1993;56(1 suppl):S54-S60.
88. Tielens ET, Forder JR, Chatham JC, Marrelli SP, Ladenson PW. Acute L-triiodothyronine administration potentiates inotropic responses to beta-adrenergic stimulation in the isolated perfused rat heart. Cardiovasc Res. 1996;32:306-310.
89. Hamilton MA. Prevalence and clinical implications of abnormal thyroid hormone metabolism in advanced heart failure [with discussion]. Ann Thorac Surg. 1993;56(1suppl):S48-S53.
90. Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J. 1998;135(2, pt 1):187-196.
91. Shanoudy H, Soliman A, Moe S, et al. Early manifestations of "sick euthyroid" syndrome in patients with compensated chronic heart failure. J Card Fail. 2001;7: 146-152.
92. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med. 1996;101:461-467.
93. Hamilton MA, Stevenson LW, Fonarow GC, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998;81:443-447.
94. Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008; 93:1351-1358.